Tevogen Bio (TVGN)
Develops ExacTcell-based T-cell therapy candidates for COVID-19, cancer and Long COVID.
Something off on this page? Send us feedback.
Develops an allogeneic T-cell therapy pipeline built on its ExacTcell platform. Its first clinical candidate, TVGN 489, targets acute COVID-19, while additional named candidates address cervical cancer, mouth and throat cancer, and Epstein–Barr-virus-associated lymphomas.
ExacTcell is Tevogen Bio's platform for developing, enriching and expanding selected cytotoxic T-cell therapies with defined targets. TVGN 489, the first clinical product from the platform, is an investigational allogeneic therapy for acute COVID-19 in vulnerable cancer patients.
The pipeline also includes TVGN 920 for cervical cancer, TVGN 960 for mouth and throat cancer, and TVGN 930 for Epstein–Barr-virus-associated lymphomas. The company has said it is prioritizing oncology and Long COVID, rather than selling approved products.
Operations are based in New Jersey and began in 2020. The business remains dependent on clinical testing, regulatory approval, and additional capital before commercialization.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.1M · Total debt $3.0M · Total assets $4.7M · Shareholders' equity −$8.9M
- Revenue
- $0
- Operating income
- −$5.7M
- Net income
- −$5.8M
No dividends on record.
| Institutions29 holders · as of Mar 31, 2026 | 3.26% | 135.8K shares | |
| Insiders9 holders · as of Jul 14, 2026 | 103.80% | 4.32M shares | |
| Adds to | 107.06% |
4.16M company shares as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (6.51M in the company's Sep 3, 2026 report, 4.16M elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
These groups come from separate filings that can overlap, so they add to 107.06%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Ryan H. SaadiInsiderdirector, 10 percent owner, officer: Chief Executive Officer | 89.08% | 3.71M | 13Dfiled Jul 14, 2026 ↗ |
Kirti DesaiInsiderofficer: Chief Financial Officer | 5.84% | 242,983 | Form 4filed Jul 10, 2026 ↗ |
Neal FlomenbergInsiderofficer: See Remarks | 1.85% | 76,940 | Form 4filed Mar 17, 2026 ↗ |
Curtis L. PattonInsiderdirector | 1.54% | 64,192 | Form 4filed Jul 10, 2026 ↗ |
Jeffrey L. FeikeInsiderdirector | 1.36% | 56,435 | Form 4filed Jul 10, 2026 ↗ |
| See all 25 → | |||
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 13, 2026 | Neal Flomenberg | officer: See Remarks | −501 | $6.40 |
| Mar 11, 2026 | Neal Flomenberg | officer: See Remarks | −452 | $7.26 |
| Mar 10, 2026 | Neal Flomenberg | officer: See Remarks | −19 | $7.75 |
- Atara Biotherapeutics
Off-the-shelf EBV-specific T-cell platform for cancers
- Cellectis (ADR)
Gene-edited, off-the-shelf allogeneic CAR-T programs
- Allogene Therapeutics
Off-the-shelf allogeneic CAR-T programs for cancer
- TScan Therapeutics
TCR-engineered T-cell therapies for cancer
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Tevogen Bio | $6.92 | −3.49% | $29.9M | — | — | — | — |
| Atara Biotherapeutics | $8.70 | −7.35% | $85.1M | — | 14.5 | 13.7 | −96.4% |
| Cellectis (ADR) | $3.26 | −1.51% | $326.4M | — | — | 4.2 | −59.2% |
| Allogene Therapeutics | $1.99 | +0.42% | $683.4M | — | — | 147.3 | — |
| TScan Therapeutics | $0.3650 | −5.68% | $23.3M | — | — | 3.3 | −65.8% |
| Median | — | 14.5 | 9.0 | −65.8% |